Phaseline

Companies › Atossa Therapeutics

Atossa Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
(Z)-endoxifen
Selective estrogen receptor modulator (SERM)
ESR1Phase 2Breast NeoplasmsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05607004(Z)-endoxifenPhase 2Breast NeoplasmsOncologyNov 2026

From the company's SEC filings

Cash of $21m on 2026-09-30; operating cash outflow about $33m a year; runway about 7 months at that burn, to May 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

ESR1 (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics GE Healthcare Novartis

Companies built like this

LeonaBio Shanghai Best-Link Bioscience Dogwood Therapeutics Curis Processa Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.